# A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

> **NCT03809663** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 251 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tezepelumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03809663
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-15
- **Primary completion:** 2020-05-12
- **Final completion:** 2020-12-22
- **Target enrollment:** 251 (ACTUAL)
- **Why stopped:** Tezepelumab as a monotherapy in atopic dermatitis did not reach the targeted efficacy level pre-established for this patient population.
- **Last updated:** 2022-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03809663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03809663, "A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03809663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*